Madrigal Pharmaceuticals(US:MDGL) Globenewswire·2025-08-05 11:00Core Insights - Madrigal Pharmaceuticals reported strong second-quarter 2025 results, driven by high demand for its product Rezdiffra, with net sales reaching $212.8 million, a significant increase from $14.6 million in the same period last year [4][7]. Corporate Strategy and Developments - The company secured a new U.S. patent for Rezdiffra, extending its protection until February 4, 2045, which is crucial for maintaining its market position [5]. - Madrigal announced a global licensing agreement for an oral GLP-1 development candidate, SYH2086, which is expected to enter clinical trials in the first half of 2026 [5]. - The company has strengthened its financial position by securing up to $500 million in senior secured credit to advance its pipeline [5]. - Positive data from a two-year study on F4c MASH patients was presented, indicating broad and sustained efficacy, which supports the ongoing MAESTRO-NASH OUTCOMES trial [5][9]. Financial Performance - Total revenues for the second quarter of 2025 were $212.8 million, compared to $14.6 million in the same quarter of 2024, reflecting a substantial increase in Rezdiffra demand [7]. - Operating expenses for the second quarter were $260.0 million, up from $177.2 million year-over-year, primarily due to increased commercial activities [7]. - The company reported a net loss of $42.3 million for the second quarter of 2025, compared to a net loss of $152.0 million in the same period last year [24]. Market Opportunity - The estimated market opportunity for F4c MASH patients in the U.S. is approximately 245,000 individuals currently under the care of liver specialists [12]. - Madrigal aims to address the needs of around 315,000 patients with moderate to advanced fibrosis in the U.S. [11]. Leadership Changes - Dan Brennan was appointed to the Board of Directors, bringing extensive experience from his previous role as Executive Vice President and Chief Financial Officer of Boston Scientific [6].